Citations

Citations to this article as recorded by  

• Integrating shear wave elastography into clinical prediction of Graves’ disease recurrence: a novel risk scoring system
  Xiao-Yun Zha, Ze-Hong Xu, Jia-Jia Dong, Liang-Xiao Xie, Peng-Bin Lai, Chang-Shun Wei, Hua-Qiang Zheng, Duo-Bin Huang, Jin-Zhi Wu
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Risk factors and outcomes of Graves’ orbitopathy after radioactive iodine therapy
  Hwa Young Ahn, Jooyoung Lee, Mina Kim, Jeong Kyu Lee
  Endocrine.2025; 90(1): 248.     CrossRef
• High TRAb Titer at Diagnosis Predicts Persistent Positivity and Relapse in Graves’ Disease after Prolonged Antithyroid Therapy
  Zimiao Chen, Jinglu Xu, Wenrui Kang, Yang Zhang, Rujun Chen, Xiaohua Gong
  Endocrinology and Metabolism.2025; 40(6): 950.     CrossRef

Whether or not Graves' hyperthyroidism can be really cured, depends on the definition of “cure.” If eradication of thyroid hormone excess suffices for the label “cure,” then all patients can be cured because total thyroidectomy or high doses of ¹³¹I will abolish hyperthyroidism albeit at the expense of creating another disease (hypothyroidism) requiring lifelong medication with levothyroxine. I would not call this a “cure,” which I would like to define as a state with stable thyroid stimulating hormone (TSH), free thyroxine, and triiodothyronine serum concentrations in the normal range in the absence of any thyroid medication. Surgery and radioiodine are unlikely to result in so-defined cures, as their preferable aim as stated in guidelines is to cause permanent hypothyroidism. Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score. At 20-year follow-up about 62% had developed recurrent hyperthyroidism, 8% had subclinical hypothyroidism, and 3% overt hypothyroidism related to TSH receptor blocking antibodies and thyroid peroxidase antibodies. Only 27% was in remission, and might be considered cured. If the definition of “cure” would also include the disappearance of thyroid antibodies in serum, the proportion of cured patients would become even lower.

Citations

Citations to this article as recorded by  

• Exploring successful treatments for upper eyelid retraction in thyroid eye disease: A scoping review
  Dominique Salh, Megan Roy Pickard, Adil Al-Mehiawi, Robin Parker, Ahsen Hussain
  Survey of Ophthalmology.2026;[Epub]     CrossRef
• Predictors of Remission in Graves’ Disease Patients Treated With Antithyroid Drugs: A Retrospective Study
  Raghad S Alzahrani, Yazeed H Aljabri, Wasan S Alzahrani, Feras M Fatani, Loay J Alghamdi, Ali S Alsudais, Suhaib Radi
  Cureus.2025;[Epub]     CrossRef
• Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question
  Chan-Hee Jung
  Endocrinology and Metabolism.2025; 40(1): 70.     CrossRef
• Thyroid peroxidase antibodies and their role in predicting outcomes in Graves’ disease treatment
  Klara Gewert, Geriolda Topi, Tereza Planck, Jan Calissendorff
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Bacteroides fragilis and propionate synergize with low-dose methimazole to treat Graves’ disease
  Xinjie Zhang, Qingxin Pan, Guixiang Yao, Danxia Kong, Haiyan Chen, Qunye Zhang, Zhe Wang, Jan Claesen
  Microbiology Spectrum.2025;[Epub]     CrossRef
• Graves’ disease: is hyperthyroidism still present 6 months after radioactive iodine treatment really a failure?
  Merve Nur Acar Tayyar, Ercan Uyanik, Mehmet Mülazimoğlu, Müge Öner Tamam, Savaş Karyağar, Meryem Eslem Biçen Altin, Fatma Zehra Yildiz Kabaca, Merve Cinoğlu Karaca
  Nuclear Medicine Communications.2025; 46(11): 1037.     CrossRef
• Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves’ disease: a nested prospective cohort study with propensity score matching
  Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima, Shintaro Iwama
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Outcomes of Radioactive Iodine Versus Surgery for the Treatment of Graves’ Disease: a Systematic Review and Meta-analysis
  Mohamed AbdAlla Salman, Mohamed Moustafa Assal, Ahmed Salman, Mohammed Elsherbiney
  Indian Journal of Surgery.2024; 86(S1): 18.     CrossRef
• Multifunctional nanoparticle-mediated combining therapy for human diseases
  Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, George Frimpong Boafo, Kosheli Thapa Magar, Yanmin Ju, Wei He
  Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
• Prenatal double-hit with aluminium and cadmium mediate testicular atrophy and hypothalamic hypoplasia: the role of oxido-nitrergic stress and endocrine perturbations
  Emmanuel Okhue, Helen Ejiro Kadiri, Patrick Chukwuyenum Ichipi-Ifukor, Benneth Ben-Azu, Samuel Ogheneovo Asagba, Fidelis Ifeakachuku Achuba, John Chukwuma Oyem
  BioMetals.2024; 37(2): 477.     CrossRef
• Surgical outcome after thyroidectomy due to Graves’ disease and Lugol iodine treatment: a retrospective register-based cohort study
  Fredric Hedberg, Henrik Falhammar, Jan Calissendorff, Robert Bränström
  Endocrine.2024; 85(1): 272.     CrossRef
• Graves disease is associated with increased risk of clinical Alzheimer’s disease: evidence from the Medicare system
  Arseniy Pavlovich Yashkin, Stanislav Kolpakov, Svetlana Ukraintseva, Anatoliy Yashin, Igor Akushevich
  Clinical Diabetes and Endocrinology.2024;[Epub]     CrossRef
• A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change
  Danilo Villagelin, David S Cooper, Henry B Burch
  The Journal of Clinical Endocrinology & Metabolism.2024; 109(11): 2956.     CrossRef
• Histopathological changes in salivary glands after radioactive iodine treatment for thyroid diseases
  Xiao Li, Jia-Zeng Su, Yan Gao, Deng-Gao Liu, Guang-Yan Yu
  Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2024; 138(3): 384.     CrossRef
• Etiologocal Analysis and Research Progress of Refractory Hypothyroidism with Thyroid Eye Disease and Thyroid Acropachy
  晓晴 戴
  Advances in Clinical Medicine.2024; 14(05): 801.     CrossRef
• The main principles of managing patients with Graves’ disease in clinical practice
  E. D. Pesheva, Yu. I. Khruleva, S. M. Deunezhewa, K. R. Enikeeva, D. Mukhambet, T. B. Morgunova, V. V. Fadeev
  Clinical and experimental thyroidology.2024; 19(3): 29.     CrossRef
• Targeting Thyroid-Stimulating Hormone Receptor: A Perspective on Small-Molecule Modulators and Their Therapeutic Potential
  Yu Zhang, Ye Tan, Zian Zhang, Xi Cheng, Jia Duan, Yi Li
  Journal of Medicinal Chemistry.2024; 67(18): 16018.     CrossRef
• Best practices in the laboratory diagnosis, prognostication, prediction, and monitoring of Graves’ disease: role of TRAbs
  Sanjay Kalra, Shahjada Selim, Dina Shrestha, Noel Somasundaram, Syed Abbas Raza, Manash P. Baruah, Saptarshi Bhattacharya, Sharvil Gadve, Ganapathi Bantwal, Rakesh Sahay
  BMC Endocrine Disorders.2024;[Epub]     CrossRef
• Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves’ Hyperthyroidism with Potassium Iodide
  Ken Okamura
  Endocrinology and Metabolism.2024; 39(6): 827.     CrossRef
• A Comprehensive Review of Thyroid Dysfunction: Hidden Player in Male Infertility
  Elizabeth Moyinoluwa Babatunde, Mathias Abiodun Emokpae
  Fertility & Reproduction.2024; 06(04): 166.     CrossRef
• Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves’ Disease: A Pilot Study
  Jin-Ying Lu, Kuan-Hua Chen, Shyang-Rong Shih, Fang-Yu Wen, Wan-Chen Wu, Ting-Chu Chen, Fu-Chang Hu
  Endocrine Practice.2023; 29(2): 89.     CrossRef
• Case of Graves’ disease recovery
  Andrey Valerievich Ushakov
  Journal of Clinical and Translational Endocrinology: Case Reports.2023; 27: 100139.     CrossRef
• Association between high mobility group box-1 circulation level and Graves' ophthalmopathy
  Mohammad Robikhul Ikhsan, Nyoman Kertia, Supanji Supanji, Bambang Udji djoko Rianto, Dhite Bayu Nugroho
  F1000Research.2023; 12: 767.     CrossRef
• New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
  Kan Chen, Yiyang Gao, Jing Li
  European Journal of Medical Research.2023;[Epub]     CrossRef
• REVIEW OF SARS-CORONAVIRUS-2 REPERCUSSIONS ON THYROID GLAND IN THE CONTEXT OF HYPERTHYROIDISM
  SHUBHAM SINGH, MONIKA, RUPA MAZUMDER, AVIJIT MAZUMDER
  International Journal of Applied Pharmaceutics.2023; : 17.     CrossRef
• Effectiveness and potential mechanism of Jiawei-Xiaoyao-San for hyperthyroidism: a systematic review
  Wenxin Ma, Xiaowen Zhang, Ruotong Zhao, Yang Tang, Xiaoyun Zhu, Longkun Liu, Mingyuan Xu, Ge Wang, Peiyue Peng, Jianping Liu, Zhaolan Liu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Associations of serum keratin 1 with thyroid function and immunity in Graves’ disease
  Chao-Wen Cheng, Wen-Fang Fang, Jiunn-Diann Lin, Appuwawadu Mestri Nipun Lakshitha de Silva
  PLOS ONE.2023; 18(11): e0289345.     CrossRef
• Management of Graves’ hyperthyroidism: present and future
  Luigi Bartalena, Eliana Piantanida, Daniela Gallo, Silvia Ippolito, Maria Laura Tanda
  Expert Review of Endocrinology & Metabolism.2022; 17(2): 153.     CrossRef
• The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
  Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
  Journal of the Endocrine Society.2022;[Epub]     CrossRef
• Efficacy of Radioiodine Therapy in Patients With Primary Hyperthyroidism: An Institutional Review From Pakistan
  Asim Munir Alvi, Umal Azmat, Waqas Shafiq, Abdul Hannan Ali Rasheed, Ahmed Imran Siddiqi, Sardar Khan, Sara Ashfaq, Hira Irfan , Humayun Bashir, Muhammad Abu Bakar, Kashif Asghar
  Cureus.2022;[Epub]     CrossRef
• Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
  Min Joo Kim, Sun Wook Cho, Ye An Kim, Hoon Sung Choi, Young Joo Park, Do Joon Park, Bo Youn Cho
  Endocrinology and Metabolism.2022; 37(3): 524.     CrossRef
• Endocrine Surgery and Pediatic Surgery Partnership Reduces Complication Rate of Pediatric Thyroidectomy
  Ali Sayan, Mehmet Üstün, Mehmet Mert, Cem Karaali, Gökhan Köylüoğlu
  Journal of Dr Behcet Uz Children s Hospital.2022; 12(2): 164.     CrossRef
• Thyroid-related adverse events induced by immune checkpoint inhibitors
  Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• A case of Hashimoto's thyroiditis following Graves' disease
  Ibtissem Oueslati, Salma Salhi, Meriem Yazidi, Fatma Chaker, Melika Chihaoui
  Clinical Case Reports.2022;[Epub]     CrossRef
• Changes in the T and B lymphocyte subset profiles upon treatment of patients with Graves’ disease with radioactive iodine
  A. A. Savchenko, M. A. Dudina, S. A. Dogadin, A. G. Borisov, I. V. Kudryavtsev, D. V. Fomina, V. D. Belenyuk
  Medical Immunology (Russia).2022; 24(5): 1007.     CrossRef
• A survey of the young person’s experience of Graves’ disease and its management
  Laura Claire Lane, Judith Rankin, Tim Cheetham
  Clinical Endocrinology.2021; 94(2): 330.     CrossRef
• Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
  Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Rajata Rajatanavin, Thep Himathongkam
  Journal of the Endocrine Society.2021;[Epub]     CrossRef
• Dosimetry-guided radioiodine therapy of hyperthyroidism: long-term experience and implications for guidelines
  Thomas Leitha, Manuela Schartel, Ingrid Hurtl, Rudolf Bednar, Franz König, Karl Mayrhofer, Flavia Pietschmann
  Nuclear Medicine Communications.2021; 42(2): 150.     CrossRef
• Practice patterns and outcomes in the management of Thai patients with Graves’ disease
  Yotsapon Thewjitcharoen, Krittadhee Karndumri, Waralee Chatchomchuan, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanathayanoroj, Nampetch Lekpittaya, Worawit Kittipoom, Tawee Anuntakulnatee, Somboon Vongterapak, Siriwan Butadej, Soontaree Nakas
  Thyroid Research.2021;[Epub]     CrossRef
• Un case report letterario di tireotossicosi in La coscienza di Zeno di Italo Svevo
  Francesco Trimarchi, Luigi Bartalena, Stefano Arieti, Roberto Toni
  L'Endocrinologo.2021; 22(2): 149.     CrossRef
• Medical treatment of thyrotoxicosis
  Lorenzo SCAPPATICCIO, Giuseppe BELLASTELLA, Maria I. MAIORINO, Luca GIOVANELLA, Katherine ESPOSITO
  The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2021;[Epub]     CrossRef
• Hiccups as a Rare Presentation of Thyrotoxicosis Triaged by an Epidural Steroid Injection
  Omar Al-Radideh, Iyad Farouji, Theodore DaCosta, Hossam Abed, Nicholas Baranestky
  Cureus.2021;[Epub]     CrossRef
• Long-term antithyroid drug therapy
  David S. Cooper
  Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 510.     CrossRef
• The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
  Maria V. Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T. Trafalis
  Cancers.2021; 13(21): 5277.     CrossRef
• Recurrence of Graves’ Disease: What Genetics of HLA and PTPN22 Can Tell Us
  Daniela Vejrazkova, Josef Vcelak, Eliska Vaclavikova, Marketa Vankova, Katerina Zajickova, Jana Vrbikova, Michaela Duskova, Petra Pacesova, Zdenek Novak, Bela Bendlova
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Most Patients with Graves’ Disease Treated with Antithyroid Drugs Eventually Require Additional Therapies
  Mary H. Samuels
  Clinical Thyroidology.2020; 32(1): 9.     CrossRef
• Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study
  Juan P. Brito, Stephanie Payne, Naykky Singh Ospina, Rene Rodriguez-Gutierrez, Spyridoula Maraka, Lindsey R. Sangaralingham, Nicole M. Iñiguez-Ariza, Victor M. Montori, Marius N. Stan
  Thyroid.2020; 30(3): 357.     CrossRef
• Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience
  Fereidoun Azizi
  Thyroid.2020; 30(10): 1451.     CrossRef
• Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
  Rui-Ting Hu, De-Shan Liu, Bin Li
  BMC Endocrine Disorders.2020;[Epub]     CrossRef
• The Concept of Cure in Thyroid Diseases
  Fereidoun Azizi
  International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
• Der Biomarker TSH bei Schilddrüsenautonomien
  K. Passek, N. Zulauf, E. Wanke, G. M. Oremek
  Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie.2020; 70(4): 177.     CrossRef
• Management of Graves’ Hyperthyroidism: More Than a Century of Progression
  Hengameh Abdi, Atieh Amouzegar
  International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
• Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
  Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Fabrizio Lo Giudice, Francesco Frasca, Antonino Belfiore, Riccardo Vigneri
  Frontiers in Endocrinology.2020;[Epub]     CrossRef
• Prediction of Relapse After Antithyroid Drugs Withdrawal: A Narrative Review
  Pei-Wen Wang
  International Journal of Endocrinology and Metabolism.2020;[Epub]     CrossRef
• Radioiodine-131 therapy (RIT) in benign thyroid diseases: Personalized prescription based on objectives with optional use of pharmacological modulators
  J. Clerc
  Médecine Nucléaire.2020; 44(4): 250.     CrossRef
• Predicting the Risk of Graves Disease Relapse: Commentary on “Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease”
  D. Gallo, M.L. Tanda, E. Piantanida
  Endocrine Practice.2020; 26(9): 1039.     CrossRef
• Integrating Five Feature Types Extracted From Ultrasonograms to Improve the Prediction of Thyroid Papillary Carcinoma
  Renxiang Zhu, Zhongyu Wang, Yifan Zhang, Bingxin Yu, Mingran Qi, Xin Feng, Chenjun Wu, Yuxuan Cui, Lan Huang, Fan Li, Fengfeng Zhou
  IEEE Access.2019; 7: 101820.     CrossRef
• Serum TSH Receptor Antibodies Fall Gradually and Only Rarely Switch Functional Activity in Treated Graves’ Disease
  Mary H. Samuels
  Clinical Thyroidology.2019; 31(8): 330.     CrossRef
• Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
  Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
  Endocrinology and Metabolism.2019; 34(3): 268.     CrossRef
• A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease
  Sandra M. McLachlan, Basil Rapoport
  Endocrine.2019; 66(2): 137.     CrossRef